Faeth Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Faeth Therapeutics CEO'su Anand Parikh, Jun2026 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 3.16% doğrudan sahiptir ve bu hisselerin değeri $ 28.21M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.7 yıl ve 0.6 yıldır.

Anahtar bilgiler

Anand Parikh

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	3.2%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Sep 18

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion

Summary I am initiating Faeth Therapeutics with a "Buy" rating following its acquisition, name change, and $200M private placement. Company's lead asset, PIKTOR, targets multi-node PAM pathway alterations in endometrial cancer and HR+/HER2- breast cancer, with key phase 2 and 1b/2 data catalysts ahead. Topline results for PIKTOR in 2nd-line advanced endometrial cancer are expected by year-end 2026, with interim breast cancer data in 2027. Company's cash runway is sufficient for near-term catalysts, but increased trial expenses suggest a likely need for additional funding within several months. Read the full article on Seeking Alpha

Analiz Makalesi • Nov 03

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Jul 02

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Mar 14

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analiz Makalesi • Aug 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Aug 09

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics press release (NASDAQ:SNSE): Q2 GAAP EPS of -$0.34 beats by $0.06. Cash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $147.6 million as of December 31, 2021. Sensei expects its current cash balance to fund operations into the first quarter of 2025.

Analiz Makalesi • Apr 18

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Nov 16

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO

Anand Parikh (40 yo)

less than a year

Görev süresi

Mr. Anand Parikh, Esq., J.D., served as Chief Operating Officer and Director at Sensei Biotherapeutics, Inc. from February 17, 2026 and serves as its Chair since 2026 and serves as its Chief Executive Offi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Josiah Craver	Senior VP of Finance	2yrs	US$409.71k	0% $ 0
Christopher Gerry	General Counsel & Secretary	4.2yrs	US$434.60k	0.0037% $ 32.9k
Anand Parikh	CEO, President & Chair	less than a year	Veri yok	3.16% $ 28.2m
Siddhartha Mukherjee	Scientific Co-Founder	less than a year	Veri yok	Veri yok
Lewis Cantley	Scientific Co-Founder	less than a year	Veri yok	Veri yok
Scott Lowe	Scientific Co-Founder	less than a year	Veri yok	Veri yok
Gregory Hannon	Scientific Co-Founder	less than a year	Veri yok	Veri yok
Karen Vousden	Scientific Co-Founder & Director	less than a year	Veri yok	0.16% $ 1.5m
Oliver Maddocks	Co-Founder & Chief Scientific Officer	less than a year	Veri yok	Veri yok
Benjamin Hopkins	Scientific Co-Founder	less than a year	Veri yok	Veri yok
Simon Knott	Scientific Co-Founder	less than a year	Veri yok	Veri yok
Marcus Goncalves	Scientific Co-Founder	less than a year	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: FTH 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anand Parikh	CEO, President & Chair	less than a year	Veri yok	3.16% $ 28.2m
Karen Vousden	Scientific Co-Founder & Director	no data	Veri yok	0.16% $ 1.5m
Robert Holmen	Independent Director	9.7yrs	US$62.22k	0.0050% $ 44.1k
Phillip Donenberg	Independent Director	less than a year	Veri yok	0% $ 0
Richard Ulevitch	Member of Immuno-Oncology Advisory Board	5.3yrs	Veri yok	Veri yok
Robert Schreiber	Member of Immuno-Oncology Advisory Board	no data	Veri yok	Veri yok
Sona Saira Ramasastry	Director	less than a year	Veri yok	Veri yok
Stephen Hahn	Director	less than a year	Veri yok	0.17% $ 1.5m
Alain Algazi	Member of Immuno-Oncology Advisory Board	no data	Veri yok	Veri yok
Daniel Sterman	Member of Immuno-Oncology Advisory Board	no data	Veri yok	Veri yok
Maura Gillison	Member of Immuno-Oncology Advisory Board	5.3yrs	Veri yok	Veri yok
Sara Pai	Member of Immuno-Oncology Advisory Board	no data	Veri yok	Veri yok

0.6yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FTH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/21 23:03
Gün Sonu Hisse Fiyatı	2026/09/21 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Faeth Therapeutics, Inc. 19 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jack Allen	Baird
Zhiqiang Shu	Berenberg
Suranjit Mukherjee	BTIG

Faeth Therapeutics Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Faeth Therapeutics, Inc. Announces Appointment of Karen Vousden to Board of Directors and Compensation Committee Member, Effective September 11, 2026

Faeth Therapeutics, Inc. Announces Management Changes

Chief Financial Officer recently bought US$406k worth of stock

Less than half of directors are independent

Sensei Biotherapeutics, Inc. Announces Executive Changes, Effective June 13, 2026

Insider recently sold US$501k worth of stock

Recent updates

Faeth Therapeutics, Inc. Announces Appointment of Karen Vousden to Board of Directors and Compensation Committee Member, Effective September 11, 2026

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion

Faeth Therapeutics Receives FDA Fast Track Designation For PIKTOR Plus Paclitaxel In Advanced Endometrial Cancer

Faeth Therapeutics, Inc. Announces Management Changes

Faeth Therapeutics Presents Pk/Pd Modeling That Informs Piktor Dose Selection in Ongoing Fth-Pik-201 Trial

Chief Financial Officer recently bought US$406k worth of stock

New major risk - Shareholder dilution

Faeth Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Less than half of directors are independent

Sensei Biotherapeutics, Inc. Announces Executive Changes, Effective June 13, 2026

Insider recently sold US$501k worth of stock

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2026

Sensei Biotherapeutics, Inc. announced that it expects to receive $199.994578 million in funding from The B Group, Inc., Balyasny Asset Management L.P., Columbia Threadneedle Investments NA, Cormorant Asset Management, LP, Fairmount Co, Logos Capital LLC, Vivo Capital LLC and other investors.

Sensei Biotherapeutics, Inc. Announces Directorate Appointments, Effective February 13, 2026

New major risk - Market cap size

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in Pd-(L)1 Resistant Tumors At the Esmo Congress 2025

New major risk - Share price stability

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug At the European Society for Medical Oncology Congress 2025

Sensei Biotherapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Price target increased by 17% to US$4.50

Sensei Biotherapeutics, Inc., Annual General Meeting, May 21, 2025

Insufficient new directors

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Price target decreased by 8.8% to US$3.88

Nasdaq Grants Second Extension Till July 7, 2025 to Sensei Biotherapeutics to Regain Compliance with Minimum Bid Price Requirement

Sensei Biotherapeutics, Inc. to Close its Research Site in Rockville, Maryland and Reduce its Workforce by Approximately 46%

Sensei Biotherapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(a)(1)

Price target decreased by 13% to US$4.33

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Announces Management Changes

High number of new directors

Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE).

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo

Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Sensei Biotherapeutics, Inc., Annual General Meeting, Jul 10, 2023

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

High number of new directors

eSensei Biotherapeutics, Inc. Announces Reduction of Total Workforce

Sensei Biotherapeutics, Inc. Announces Executive Changes

High number of new and inexperienced directors

Sensei Biotherapeutics, Inc. Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Apeiron Investment Sends a Letter to Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Sensei Biotherapeutics, Inc. Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, A Ph-Selective Vista-Blocking Antibody

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 2500 Value Index

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

Price target decreased to US$8.00

High number of new and inexperienced directors

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Price target decreased to US$11.00

Chairman of The Board recently bought US$80k worth of stock

Chairman of The Board recently bought US$136k worth of stock

Chairman of The Board recently bought US$53k worth of stock

Independent Director recently bought US$57k worth of stock

Independent Director recently bought US$250k worth of stock